What does “pivotal clinical trials” mean?
“Pivotal clinical trials” are the key studies that generate the clinical evidence regulators rely on to approve a medicine. They usually assess whether the drug works for its intended use and whether the benefits outweigh risks, using endpoints such as how well patients respond to treatment and safety outcomes.
For an original (reference) biologic, pivotal trials are often the main dataset submitted to support approval. For a biosimilar, the development plan is different: biosimilars generally do not repeat the entire original program at full scale. Instead, they rely on a stepwise approach that compares the biosimilar to the reference product and fills remaining uncertainties with targeted clinical evidence.
Are pivotal trials required for biosimilars?
A biosimilar typically is not approved on “full pivotal trials” the way an original biologic often is. That’s because biosimilar approval is driven by totality of evidence: extensive analytical (quality) comparisons plus nonclinical/clinical data designed to confirm there are no meaningful differences versus the reference product.
In practice, many biosimilars use clinical studies that are often smaller and more focused than the reference product’s pivotal trials. These may be used to confirm similarity in areas that matter most clinically (for example, pharmacokinetics, pharmacodynamics, immunogenicity, and sometimes effectiveness in sensitive populations or indications), rather than establishing efficacy from scratch.
How does biosimilar development replace “pivotal” evidence?
Biosimilar programs usually follow a “comparability” logic. The more the analytical and functional similarity is demonstrated, the less additional clinical data is needed. Clinical work still matters, but it is used to address specific residual questions, such as:
- whether exposure (pharmacokinetics) matches the reference product
- whether immune responses (immunogenicity) are comparable
- whether there is comparable clinical performance where needed to support extrapolation across indications
So, even when a biosimilar has clinical trials, they are often designed to demonstrate similarity rather than to independently prove the entire treatment landscape.
What clinical studies do biosimilars typically run?
Biosimilars commonly include:
- PK/PD and comparative immunogenicity studies
- one or more clinical effectiveness/safety studies in an indication considered “sensitive” for demonstrating similarity
- safety monitoring focused on known risks, especially immunogenicity-related concerns
These studies can be described as “pivotal” in a general sense (because they are used to support approval), even though they are usually not as large or comprehensive as the reference product’s initial pivotal program.
When would a biosimilar need more extensive trials?
More extensive clinical work may be needed if there are uncertainties that cannot be resolved through quality, nonclinical, or early clinical comparisons. Examples include:
- meaningful differences observed in analytical testing or functional assays that require further clinical confirmation
- switching formulation/process in a way that affects critical quality attributes
- higher-risk immunogenicity signals that need stronger comparative evidence
- indications where extrapolation is more complex and regulators want stronger clinical support
How does “extrapolation” relate to biosimilar trials?
Biosimilars often seek approval for multiple indications of the reference product through extrapolation, meaning they can be approved beyond the indication studied in the clinical trial if similarity is established and the mechanism of action, receptors/targets, and safety/efficacy considerations are sufficiently comparable.
This can reduce the need for separate, full pivotal trials in every indication, but it depends on the specific biologic and regulatory assessment.
Where can you read about specific biosimilar approvals and evidence packages?
For biosimilar and biologic approval history tied to patents and exclusivity (which often affects timelines for when biosimilars can launch), DrugPatentWatch.com can be a useful resource. For example, their biosimilar pages often summarize development/launch context and relevant intellectual property [1].
Sources
[1] https://www.drugpatentwatch.com/